Echo Biotech closes nearly 100M yuan Series B to develop next-gen exosome regenerative therapies

Recently, Echo Biotech, a leading enterprise in China's exosome technology field, has completed a nearly 100 million yuan Series B financing round. This round was again led by its existing shareholder ZBJL Capital, with participation from Guosheng Capital.

Founded in 2017, this exosome technology company has secured several cumulative financing rounds totaling hundreds of millions of yuan. To date, it has received multiple investments (two or more rounds) from institutions including ZBJL Capital, LF Capital, TigerYeah Capital, Volcanics Venture, and Baidu Venture, demonstrating continuous recognition and follow-on investment from existing shareholders. The completion of this financing round will support the company in developing a new generation of exosome-based regenerative therapies and systemic anti-aging solutions, accelerating the practical application of exosome treatments.

Tian Xiaoling, Partner at ZBJL Capital, stated: "Since our previous investment, we are pleased to witness Echo Biotech's significant breakthroughs in exosome technology platform iteration, GMP system construction, and commercial expansion, which have further solidified its leading position in the industry and established it as a critical bridge connecting basic research with clinical application. The exosome sector is transitioning from technological exploration to a crucial phase of industrial breakthrough. The Echo Biotech team has demonstrated exceptional insight and execution capabilities, with founders possessing both scientific vision and business pragmatism, enabling the company to rapidly build competitive moats during the early industrialization stage. We will continue to mobilize ecosystem resources to support Echo Biotech's evolution from a technology leader to an industry definer, jointly driving innovation and development in the exosome field to create long-term value for human health."

Guosheng Capital stated: "Exosomes represent the next industry-level opportunity in regenerative medicine. We are delighted to support the company's innovation commercialization through this investment, facilitating its landing in Chengdu Tianfu International Bio-town. Echo Biotech possesses absolute advantages in exosome research and has established leading comprehensive capabilities in exosome engineering and raw material production, achieving self-sustaining commercial viability. We have full confidence in Echo Biotech's development and will not only consistently support its R&D efforts but also promote comprehensive synergy with Chengdu Tianfu International Bio-town, helping the company grow into an internationally leading enterprise in innovative exosome applications."

Regarding this financing round, Echo Biotech CEO Kong Guanyi stated: "We extend our sincere gratitude to both new and existing shareholders for their consistent recognition and support. This year, the inclusion of exosome therapy in the Advanced Therapy Medicinal Products (ATMP) classification marks a significant inflection point for its clinical application. Through years of focused efforts and accumulation, Echo Biotech has built a full-chain advantage spanning from exosome 'understanding' and 'engineering' to industrial 'application'. The completion of this funding round will empower the company to develop a new generation of exosome-based regenerative therapies and systemic anti-aging solutions for global patients and users, accelerating the practical implementation of exosome treatments."

Echo Biotech CTO Zhao Libo added: "We will continue to increase investment in fundamental exosome technology R&D, continuously enrich and optimize the efficacy and functionality of novel exosome-based drug delivery systems, improve exosome production processes and quality, and rapidly advance multiple core drug pipelines through preclinical and clinical studies. We strive to achieve the industrialization and clinical application of innovative drugs as soon as possible."